Introduction:
The Influx Healthtech SME IPO hits the market on June 18, 2025, and investors are watching closely. This Mumbai-based pharma and healthcare player plans to raise â‚ą58.57 crore through a mix of fresh issue and offer for sale.
The price band is set at â‚ą91 to â‚ą96 per share. Retail investors can apply for just 1 lot (1,200 shares) with an investment of â‚ą1,15,200. HNIs must apply for at least 2 lots. The IPO includes a fresh issue of â‚ą48 crore and an OFS of â‚ą10.56 crore.
The company expects to list on NSE SME by June 25. With strong financials, WHO-GMP certified manufacturing, and a wide product range, Influx Healthtech could offer a healthy opportunity. But will it deliver on the listing?
Let’s break it down—GMP, timeline, business strengths, and more.
đź“‹ Influx Healthtech SME IPO Details
| Particulars | Details |
|---|---|
| IPO Name | Influx Healthtech SME IPO |
| IPO Opening Date | June 18, 2025 |
| IPO Closing Date | June 20, 2025 |
| IPO Type | Book Build Issue |
| Face Value | â‚ą10 per share |
| Price Band | ₹91 – ₹96 per share |
| Lot Size | 1,200 shares |
| Minimum Retail Investment | â‚ą1,15,200 (1 lot) |
| Minimum HNI Investment | â‚ą2,30,400 (2 lots) |
| IPO Issue Size | â‚ą58.57 crore |
| – Fresh Issue | ₹48.00 crore |
| – Offer for Sale (OFS) | ₹10.56 crore |
| Retail Quota | Not less than 35% of net issue |
| Listing At | NSE SME |
| Promoter Holding (Pre-IPO) | 99.85% |
| Promoter Holding (Post-IPO) | 73.53% |
Influx Healthtech SME IPO – Important Dates
| IPO Activity | Date |
|---|---|
| IPO Opening Date | June 18, 2025 |
| IPO Closing Date | June 20, 2025 |
| Basis of Allotment | June 23, 2025 (Tentative) |
| Refunds Initiation | June 24, 2025 (Tentative) |
| Credit of Shares to Demat | June 24, 2025 (Tentative) |
| Listing Date on NSE SME | June 25, 2025 (Tentative) |
đź”” Note: All dates are subject to change based on final announcements.
Influx Healthtech SME IPO Objective
Company aims to utilise the net proceeds from the IPO to strengthen its manufacturing infrastructure and support future growth. Here’s a breakdown of where the funds will go:
| Purpose | Estimated Amount (â‚ą Cr) |
|---|---|
| Capital expenditure for setting up Nutraceutical Division facility | â‚ą22.60 |
| Capital expenditure for setting up Veterinary Food Division facility | â‚ą11.59 |
| Purchase of machinery for Homecare and Cosmetic Division | â‚ą2.76 |
| General Corporate Purposes | Balance amount |
đź’ˇ The company plans to expand its capacity and product offerings by investing in specialised divisions and equipment, which will help drive scale and operational efficiency.
Company Overview – Influx Healthtech Limited
Founded in 2020, Influx Healthtech Limited is a fast-growing Mumbai-based healthcare company that has carved out a strong niche as a Contract Development and Manufacturing Organization (CDMO). The company provides end-to-end manufacturing and formulation development services across diverse verticals like nutraceuticals, cosmetics, ayurvedic products, veterinary supplements, APIs, and homecare.
With a robust manufacturing footprint in Thane, Maharashtra, Influx operates across three dedicated facilities covering a combined 36,676 sq. ft. These plants are fully certified with global standards like WHO-GMP, ISO 22000, HACCP, ISO 14001, and Halal, reflecting its commitment to quality, safety, and international compliance. It also holds FDA approvals for several products.
Product Portfolio Highlights:
- Nutraceuticals: Tablets, capsules, powders, jellies, gummies, oral films, softgels, and gym supplements
- Cosmetics: Skincare, haircare, beard care, face masks, soaps
- Ayurvedic & Herbal: Topicals, tablets, powders, creams, and liquids
- Veterinary Supplements: Oral sprays, powders, boluses, ointments for pets and livestock
- Homecare: Household cleaning products including floor and bathroom cleaners, phenyle
Promoters & Leadership
The company is led by Mr. Munir Abdul Ganee Chandniwala, a seasoned pharma professional with over 18 years of experience across nutraceuticals and contract manufacturing. He holds a Ph.D., an MBA from Atharva School of Business, and is also a registered pharmacist.
Co-founder Ms. Shirin Munir Ahmed Chandniwala brings over 12 years of experience in financial management and currently leads the company’s budgeting, operations, and strategy.
Business Model & Capabilities
Influx supports its B2B clients through all phases — from formulation to production to regulatory guidance — helping them accelerate product rollouts. Its R&D division provides:
- Formulation development
- Process scale-up
- Analytical method development
The company positions itself as a one-stop partner for emerging and established nutraceutical and cosmetic brands seeking high-quality contract manufacturing.
Clientele
As of FY2025, the company has served 571 clients, including names like:
- Bling Brands Pvt. Ltd.
- Evoq Business Ventures LLP
- Bruder Life Science
- HSHS Nutraceuticals Ltd.
- Bigflex Lifescience Pvt. Ltd.
These long-standing relationships highlight Influx Healthtech’s reputation for reliability, scalability, and compliance.
Influx Healthtech SME IPO – Financial Performance
Influx Healthtech Limited has shown consistent growth in its topline and profitability over the past three financial years. The company’s strong EBITDA margins and improving PAT margins reflect operational efficiency and a scalable business model.
Key Financial Highlights (â‚ą in Crores)
| Particulars | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue from Operations | 76.05 | 99.97 | 104.85 |
| EBITDA | 10.72 | 16.96 | 20.57 |
| EBITDA Margin (%) | 14.10% | 16.96% | 19.62% |
| Profit After Tax (PAT) | 7.20 | 11.12 | 13.37 |
| PAT Margin (%) | 9.46% | 11.13% | 12.75% |
| Return on Equity (ROE) | 61.76% | 48.85% | 36.98% |
| Return on Capital Employed | 78.60% | 65.58% | 49.17% |
| Debt to Equity Ratio | 0.07 | 0.01 | 0.01 |
| Fixed Asset Turnover Ratio | 12.02 | 7.28 | 5.59 |
đź’ˇ Key Takeaways:
- Revenue Growth: Revenue grew from â‚ą76.05 Cr in FY23 to â‚ą104.85 Cr in FY25, a CAGR of over 17%.
- Profitability Surge: PAT increased 85% over two years, from â‚ą7.20 Cr to â‚ą13.37 Cr.
- Efficient Cost Control: Cost of goods sold as a % of revenue improved from 79.64% in FY23 to 73.17% in FY25.
- Lean Debt Profile: Minimal debt with a Debt-to-Equity ratio of just 0.01 in FY25.
- Healthy Working Capital: Net working capital cycle reduced from 53 days to just 18 days, indicating strong operational efficiency.
With robust financials, scalable infrastructure, and a wide client base, Influx Healthtech positions itself as a promising contender in the SME IPO space.
Influx Healthtech SME IPO – Peer Comparison & Valuation
When it comes to evaluating any SME IPO, comparing the company’s valuation against its peers provides a clearer investment perspective. Let’s explore how Influx Healthtech stacks up against listed players in the contract manufacturing and healthcare sector.
Valuation Snapshot
| Metric | Pre-IPO | Post-IPO |
|---|---|---|
| Earnings Per Share (EPS) | â‚ą7.36 | â‚ą5.77 |
| Price-to-Earnings (P/E) | 13.04x | 16.63x |
At the upper price band of â‚ą96, the post-issue P/E ratio stands at 16.63x, which appears reasonably priced when compared to other players in the same sector.
Peer Comparison
| Company | EPS (â‚ą) | NAV (â‚ą) | P/E (x) | RoNW (%) |
|---|---|---|---|---|
| Sudarshan Pharma Industries Ltd | 0.66 | 5.30 | 48.28 | 12.45% |
| Quest Laboratories Limited | 8.28 | 49.92 | 10.38 | 16.58% |
| Influx Healthtech Limited | 7.36 | 19.91 | 16.63* | 36.98% |
*Post-IPO P/E based on upper price band
What It Means for Investors:
- Strong RoNW: Influx Healthtech boasts a Return on Net Worth (RoNW) of 36.98%, significantly higher than peers—an indicator of solid financial efficiency.
- Healthy EPS: Even after dilution, an EPS of â‚ą5.77 remains competitive.
- Reasonable Valuation: While its P/E is slightly higher than Quest Laboratories, the premium seems justified considering its high margins, growth momentum, and minimal debt.
With strong profitability metrics and quality certifications, Influx Healthtech offers an attractive play in the fast-growing CDMO (Contract Development & Manufacturing Organization) segment.
Influx Healthtech SME IPO GMP Today (Grey Market Premium)
The Influx Healthtech SME IPO GMP (Grey Market Premium) has begun generating buzz among investors ahead of the listing. Here’s the latest GMP update to help you gauge market sentiment before investing.
GMP Trend & Listing Estimate
| Date | IPO Price | GMP (â‚ą) | Estimated Listing Price (â‚ą) | Estimated Profit/Loss (â‚ą per lot) |
|---|---|---|---|---|
| 17-June-2025 | â‚ą96.00 | â‚ą40 (41.67%) | â‚ą136 | â‚ą48,000 (for 1 lot of 1,200 shares) |
⚠️ Disclaimer: GMP is an unofficial and speculative indicator. It doesn’t guarantee listing performance or allotment success. Please invest with caution.
What Does the GMP Indicate?
- The current GMP of â‚ą40 suggests listing gains of 41.67%, indicating strong demand in the grey market.
- An estimated listing price of ₹136 hints at optimistic sentiment due to the company’s financials, growth outlook, and niche presence in the CDMO space.
- With retail quota at 35% and a relatively small issue size, oversubscription chances are high, possibly making allotment competitive.
Stay tuned as we keep updating the GMP status daily during the IPO window to help you make informed decisions. We Find a very informative channel on Telegram for IPO update, you can join that too for regular IPO & GMP update- For join The hidden Gem Click Here.
Influx Healthtech SME IPO – Final Verdict
Short-Term View: Listing Pop Likely
The Influx Healthtech SME IPO shows strong grey market signals (GMP â‚ą40), reflecting robust investor interest and a potential listing gain of over 40%. With a niche presence in CDMO, solid EBITDA margins, and a lean debt profile, the IPO is likely to get oversubscribed across categories. If GMP holds, short-term investors may look at a quick exit post-listing for decent profits.
Long-Term View: Fundamental Growth Potential
For long-term investors, Influx Healthtech presents a compelling growth story in the nutraceutical, veterinary, and cosmetic contract manufacturing space, which is expanding globally.
- Healthy revenue and PAT growth over 3 years
- ROE at ~37% and ROCE near 49%
- Diversified product base with WHO-GMP, ISO & FDA certifications
- Almost zero debt, scalable infrastructure, and long-term B2B client stickiness
However, one should also note the slightly stretched post-issue valuation (P/E ~16.6x) and dependence on third-party brands. Long-term investors must track execution on upcoming capacity expansions and sustained margin growth.
Allotment Strategy: Go All In (Retail)
- Retail investors can apply for 1 lot (1,200 shares) at â‚ą115,200
- Minimum HNI application is 2 lots (2,400 shares)
- Given the buzz and GMP, expect high subscription, especially in retail and HNI categories.
- If your goal is listing gain, apply through multiple demat accounts (within SEBI norms) to improve allotment odds.
đź“Ą Want to apply hassle-free? Open your FREE Demat account with Angel One today and never miss a hot IPO!
Ad
Open FREE AngelOne Demat Account
Open a free demat and trading account. Get Free Expert Advisory for Trading and Investment.Â
FAQs – Influx Healthtech SME IPO
1. What is the Influx Healthtech SME IPO opening and closing date?
The IPO opens for subscription on June 18, 2025, and closes on June 20, 2025.
2. What is the price band for Influx Healthtech SME IPO?
The price band is set at â‚ą91 to â‚ą96 per share.
3. What is the minimum lot size for retail investors?
Retail investors can apply for 1 lot, which consists of 1,200 shares, requiring an investment of â‚ą115,200.
4. What is the GMP (Grey Market Premium) of Influx Healthtech SME IPO?
As of June 17, 2025, the GMP is reported at â‚ą40, indicating an estimated listing price of â‚ą136.
5. What is the Influx Healthtech IPO issue size?
The total issue size is â‚ą58.57 crore, which includes a fresh issue of â‚ą48 crore and an offer for sale of â‚ą10.56 crore.
6. What is the tentative listing date of Influx Healthtech IPO?
The IPO is expected to list on the NSE SME platform on June 25, 2025.
7. Who are the promoters of Influx Healthtech Limited?
The company is promoted by Mr. Munir Abdul Ganee Chandniwala and Ms. Shirin Munir Ahmed Chandniwala.
8. What does Influx Healthtech do?
Influx Healthtech is a contract manufacturer (CDMO) involved in producing nutraceuticals, cosmetics, ayurvedic/herbal, veterinary supplements, APIs, and homecare products.
9. Is there any anchor investor portion in this SME IPO?
No, the IPO does not have a separately disclosed anchor investor portion.
10. What is the promoter holding post-IPO?
After the IPO, promoter shareholding will reduce from 99.85% to 73.53%.
11. What is the allotment date of the Influx Healthtech IPO?
The basis of allotment is expected to be finalized on June 23, 2025.
12. How can I check my allotment status for Influx Healthtech IPO?
You can check allotment status on the registrar’s website or via NSE SME platform using your PAN, DP ID, or application number.
13. Can HNIs apply in this IPO?
Yes. The minimum HNI application is 2 lots (2,400 shares), costing approximately â‚ą2.30 lakhs.
14. What is the PE ratio of Influx Healthtech IPO?
The post-issue P/E ratio is approximately 16.63x, based on FY25 diluted EPS of â‚ą5.77.
15. Is Influx Healthtech IPO good for long-term investment?
The company has shown consistent growth in revenue and profits, maintains strong ROE and EBITDA margins, and operates in a niche high-growth CDMO space. However, investors should also evaluate valuation and scalability risks before investing long-term.
Related Articles
India Becomes the Cheapest Manufacturing Hub: Stocks Set to Win Big
Get FREEE Updates and News Straight to your inbox!
Join 100+ Subscribers for exclusive access to our Monthly Newsletter with inside Stock Market, IPO, Top Broker, Market UpdatesÂ
